As we move into the final days of 2020, I would like to wish you a happy holiday season and start of 2021.
The conclusion of one year is generally a time for reflection. We analyze our achievements, and the issues we faced, and contemplate our plans for the future considering our obligations to others.
This year has been turbulent, not only because of the professional challenges the pandemic has created, but also the strain that it has placed on us and our families. Despite these challenges, we were able to successfully hold our 28th biennial congress virtually on a global scale, and continue to share knowledge throughout our worldwide community.
In the coming year, we will continue to focus on expanding access to transplantation through global collaborations with transplant healthcare professionals, national and regional societies and legislators. As a global community, we aim to overcome the social, legislative and ethical challenges that organ donation and transplantation are facing around the world.
I look forward to working with you all in the coming year.
From all of us at TTS, we wish you and your loved ones a safe, healthy and joyful holiday season.
Women in Transplantation (WIT) initiative of The Transplantation Society will provide funding to an Early Career Researcher to support research focusing on sex and gender issues relevant to solid organ transplantation.
This initiative was made possible with support with One Lambda, a Thermo Fisher Scientific brand, and Sanofi, with each supporting one award.
The spectrum of studies includes basic, clinical and translational. This individual should have spent two years or less performing research relevant to solid organ transplantation since obtaining their last degree (PhD, MD, MSc, PharmD, or equivalent). This work may represent a continuation of current research or a novel aspect of work. The mentor should have expertise in transplantation or immunology but need not be an investigator with known expertise in gender or sex.
Read the first issue of the DICG newsletter. This is brought to you on behalf of the executive council of the Declaration of Istanbul Custodian Group (www.declarationofistanbul.org) which works to protect and promote the principles enunciated in the Declaration of Istanbul (DOI), a landmark document in the history of global transplantation.
Dr. Jeremy R. Chapman, Editor-in-Chief, Transplantation
Luan D, Dadhania DM, Ding R, et al.
Transplantation: October 7, 2020 - Volume Online First
Coming from the New York group at Cornell, this study of mRNA in the urine of kidney transplant patients investigated using PCR assays and measuring absolute copy numbers of transcripts for FOXP3, CD25, CD3E, perforin, and 18S rRNA. Testing around 4000 urine samples from 480 recipients this single center study with prospectively enrolled patients showed that 18S rRNA normalized levels of mRNA for FOXP3, CD25, CD3E, and perforin, were diagnostic of T Cell Mediated Rejection, with FOXP3 mRNA level predicting independent of clinical variables. The study is worth a careful consideration as to how these data and this test might fit into the protocols for monitoring kidney transplant recipients in the future.
In this ongoing, double-blind, phase 1–3 trial involving nonhospitalized patients with Covid-19, two fully human, neutralizing monoclonal antibodies against SARS-CoV-2 spike protein, used in a combined cocktail (REGN-COV2) to reduce the risk of the emergence of treatment-resistant mutant virus. Patients were randomly assigned (1:1:1) to receive placebo, 2.4 g of REGN-COV2, or 8.0 g of REGN-COV2 and were prospectively characterized at baseline for endogenous immune response against SARS-CoV-2. Data from 275 patients are reported. The least-squares mean difference (combined REGN-COV2 dose groups vs. placebo group) in the time-weighted average change in viral load from day 1 through day 7 was −0.56 log10 copies per milliliter (95% confidence interval [CI], −1.02 to −0.11) among patients who were serum antibody– negative at baseline and −0.41 log10 copies per milliliter (95% CI, −0.71 to −0.10) in the overall trial population. In this interim analysis, the REGN-COV2 antibody cocktail reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline. Safety outcomes were similar in the combined REGN-COV2 dose groups and the placebo group.
Patients hospitalized with Covid-19 pneumonia who were not receiving mechanical ventilation were randomly assigned (in a 2:1 ratio) to receive standard care plus one or two doses of either tocilizumab (8 mg per kilogram of body weight intravenously) or placebo. A total of 389 patients underwent randomization, and the modified intention-to-treat population included 249 patients in the tocilizumab group and 128 patients in the placebo group. The cumulative percentage of patients who had received mechanical ventilation or who had died by day 28 was 12.0% (95% confidence interval [CI], 8.5 to 16.9) in the tocilizumab group and 19.3% (95% CI, 13.3 to 27.4) in the placebo group (hazard ratio for mechanical ventilation or death, 0.56; 95% CI, 0.33 to 0.97; P=0.04 by the log-rank test). Clinical failure as assessed in a time-to-event analysis favored tocilizumab over placebo (hazard ratio, 0.55; 95% CI, 0.33 to 0.93). Death from any cause by day 28 occurred in 10.4% of the patients in the tocilizumab group and 8.6% of those in the placebo group (weighted difference, 2.0 percentage points; 95% CI, –5.2 to 7.8). In the safety population, serious adverse events occurred in 38 of 250 patients (15.2%) in the tocilizumab group and 25 of 127 patients (19.7%) in the placebo group. In hospitalized patients with Covid-19 pneumonia who were not receiving mechanical ventilation, tocilizumab reduced the likelihood of progression to the composite outcome of mechanical ventilation or death, but it did not improve survival. No new safety signals were identified.within the gene encoding dipeptidyl peptidase 9 (DPP9), and on chr21q22.1 (rs2236757, p=4.99 ×× 10-8) in the interferon receptor gene IFNAR2. This study supports of a causal link from low expression of IFNAR2, and high expression of TYK2, to life-threatening disease; transcriptome-wide association in lung tissue revealed that high expression of the monocyte/macrophage chemotactic receptor CCR2 is associated with severe Covid-19.
The Transplantation Society (TTS) and our journal Transplantation have developed online resources to keep you informed on the Coronavirus (COVID-19) outbreak.
We are also requesting contributions and news from the transplant community to be sent to email@example.com for inclusion on our resources page.
In this dashboard, you will find links to TTS and other global and regional resources, as well as interactive maps, publications and webinars. We encourage you to explore this dashboard and share with your colleagues.
Editors and contributors to Transplantation have shared their thoughts on how they are dealing with the current crisis. While we understand that the information of today may be quite different tomorrow in this fast-moving pandemic, this report will open our forum of an international exchange on COVID for the transplant community.
Please send your own contributions and news to firstname.lastname@example.org for inclusion on our resources page.
Dec. 15 - Study findsthere is not a statistically significant difference in eGFR between kidney recipients of HCV positive and negative donors.
Dec. 16 - By studying the roles of an inflammatory protein and antibodies in chronic rejection after lung transplantation, researchers discover possibilities for new treatments.
Dec. 15 - When determining whether kidneys are suitable for transplantation in the United States, biopsy analyses don't provide useful information beyond standard donor and recipient characteristics. Many kidneys discarded based on biopsy findings would likely benefit U.S. patients who are waiting for a transplant.
Dec. 17 - Scientists can already grow skin in lab to replace that which has been destroyed by burns. Now they're working on other organs. In 2021, we will see significant breakthroughs around how artificial organs function, while the technology used to produce them will take them one step closer to use in the clinic.